Αρχική World News Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients with...

Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients with MSI/dMMR Stage III Colon Cancer

A large analysis of data from twelve trials evaluating the efficacy of adjuvant fluoropyrimidine with or without oxaliplatin in patients with stage III colon cancer found that the addition of oxaliplatin to fluoropyrimidine improved survival over fluoropyrimidine alone in those patients whose tumours were N1 stage and also demonstrated microsatellite instability (MSI), deficient DNA mismatch repair (dMMR). These findings appear in an article by Romain Cohen of the Medical Oncology Department Saint-Antoine Hospital, Sorbonne Université in Paris, France and co-investigators that was published on 23 December 2020 in the Journal of Clinical Oncology.

This study was prompted by unresolved questions regarding the efficacy of adjuvant fluoropyrimidine with or without oxaliplatin in patients with stage III colon cancer whose tumors demonstrate MSI/dMMR, and whether MSI is a prognostic factor.

The investigators conducted this analysis of 12 clinical trials using the individual patient data of more than 5000 patients with stage III colon cancer who underwent fluoropyrimidine-based adjuvant therapy contained in the ACCENT database. This analysis included data from the NCCTG-78-48-52, FFCD, INT-0035, NCIC, NCCTG-87-46-51, GIVIO, MOSAIC, C07, C08, AVANT, N0147, and PETACC trials. 

The effect of fluoropyrimidine with or without oxaliplatin on disease-free survival (DFS) and overall survival (OS) in these patients was evaluated using stratified Cox models that adjusted for demographic and clinicopathological factors.

The investigators identified 5,457 patients with immunohistochemistry- or PCR-confirmed MSI status; of these 609 (11.2%) patients were MSI and 4848 (88.8%) had microsatellite stable (MSS) tumours.

Oxaliplatin addition benefits patient with MSI tumours

According to two randomised controlled trials evaluating fluoropyrimidine with and without oxaliplatin in 185 patients with MSI tumours, OS was significantly improved with the addition of oxaliplatin (adjusted hazard ratio [aHR] 0.52, confidence interval [CI] 0.28-0.93).

In additional trials evaluating fluoropyrimidine plus oxaliplatin in 4,250 patients, 461 patients were MSI and 3789 were MSS. In these trials, MSI was associated with better OS in patients having N1 status compared with MSS (aHR 0.66; 95% CI 0.46-0.95). However, this result was not reflected in the N2 patient population where OS following adjuvant fluoropyrimidine plus oxaliplatin was similar between MSI and MSS patients (aHR 1.13; 95% CI 0.86-1.48; p interaction = 0.029).

Similar results were observed for DFS in all analyses.

Of the factors investigated, no interaction was observed between MSI status and T stage, primary tumour sidedness, or BRAFV600E mutational status (interaction p = 0.12). However, MSI prognostic effects were found to be dependent on the N stage category (interaction test for OS, p value = 0.029).

As compared with MSS patients, among MSI patients receiving fluoropyrimidine plus oxaliplatin the independent prognosticators for OS were T stage (aHR 2.09; 95% CI 1.29-3.38) and N stage (aHR 3.57; 95% CI 2.32-5.48). This significant interaction was confirmed for DFS, which demonstrated an excess of events in the first two years of follow-up in the MSI N2 population compared with patients with MSS N2, although the log-rank test was not significant.


Based on these findings, the authors concluded that the addition of oxaliplatin to fluoropyrimidine improved OS and DFS in patients with MSI stage III colon cancer. They also found that MSI was associated with better outcomes, as compared with MSS patients, in patients with N1, but not N2 disease.

The authors wrote that this meta-analysis of individual patient data demonstrates that the combination of oxaliplatin plus fluoropyrimidine should be the standard-of-care adjuvant treatment for patients with MSI/dMMR stage III colon cancer.

Furthermore, they recommended that N stage should be at least a stratification parameter in future trials involving the MSI/dMMR population.

This study was supported by the US National Cancer Institute, the ARCAD foundation, and research grants from the Nuovo-Soldati Foundation, ARC Foundation for Cancer Research, and Servier Institute.


Cohen R, Taieb, J, Fiskum J et al. Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. Journal of Clinical Oncology; Published online 23 December 2020. DOI: https://doi.org/10.1200/JCO.20.01600.


Προηγούμενο άρθροDiscovering the BRCA2 gene – 25 years on
Επόμενο άρθροUnderstanding Serving Sizes


Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...
- Advertisment -

Ροή Ειδήσεων

Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of Adjuvant Imatinib in Localised GIST

Final analysis of the EORTC Soft Tissue and Bone Sarcoma Group, the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and...

Pink Van Makes the Rounds Throughout Rural New Zealand to Offer Free Breast Health Advice

Many of us have questions about breast cancer prevention or screenings. Getting lost in a Google rabbit hole can sometimes be overwhelming and could...

How My Inherited Cancer Diagnosis Has Made Me a Better Oncologist

Dr. Lewis is Director of Gastrointestinal Oncology at Intermountain Healthcare Utah; Vice President of American Multiple Endocrine Neoplasia Support; Head of the Communications Committee...

FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High PD-L1 Expression

On 22 February 2021, the US Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with...

Five-Year Outcomes with CAR T Cell Therapy

The results of 5-year follow-up in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma who were treated with CD19-directed,...

Countdown to 100,000 OncoLife Survivorship Care Plans: How it all started

In April of 2007, OncoLink launched the OncoLife Survivorship Care Plan, a tool to create care plans for people who have survived cancer. As...